Search
GSK-356278
go.drugbank.com/drugs/DB12542InvestigationalGsk356278 has been used in trials studying the treatment and basic science of Anxiety Disorders, Huntington Disease, Depressive Disorder, Huntingtons Disease, and Depressive Disorder, Major, among others
ABT-560
go.drugbank.com/drugs/DB06093ExperimentalABT-560 is a neuronal nicotinic receptor (NNR) modulator, which has shown promise in preclinical models relevant for the treatment of cognitive deficits.
Endostar
go.drugbank.com/drugs/DB11727InvestigationalEndostar has been investigated for the treatment of Non-small Cell Lung Cancer.
Depatuxizumab mafodotin
go.drugbank.com/drugs/DB11731InvestigationalDepatuxizumab/Denintuzumab mafodotin has been used in trials studying the treatment of Lymphoma, Gliosarcoma, Glioblastoma, Malignant Glioma, Squamous Cell Tumors, and Glioblastoma Multiforme.
Spebrutinib
go.drugbank.com/drugs/DB11764InvestigationalSpebrutinib has been used in trials studying the treatment of Rheumatoid Arthritis, Lymphoma, Large B-Cell, Diffuse, and Leukemia Lymphocytic Chronic B-Cell.
Dexmecamylamine
go.drugbank.com/drugs/DB11807InvestigationalDexmecamylamine has been used in trials studying the basic science and treatment of Patients, Depression, Drug Abuse, Pharmacokinetics, and Renal Impairment, among others.
TMC-647055
go.drugbank.com/drugs/DB11822InvestigationalTMC647055 has been used in trials studying the treatment of Hepatitis C, Chronic Hepatitis C, Hepatitis C, Chronic, and Chronic Hepatitis C Virus.
Mocetinostat
go.drugbank.com/drugs/DB11830InvestigationalMocetinostat has been used in trials studying the treatment of Lymphoma, Urothelial Carcinoma, Relapsed and Refractory, Myelodysplastic Syndrome, and Metastatic Leiomyosarcoma, among others.
JNJ-39393406
go.drugbank.com/drugs/DB11867InvestigationalJNJ-39393406 has been used in trials studying the treatment and basic science of DEPRESSION, Schizophrenia, Smoking Cessation, Cognition Disorders, and Alzheimer's Disease.
STI-1499
go.drugbank.com/drugs/DB16487InvestigationalSTI-1499 (COVI-GUARD was under investigation in clinical trial NCT04454398 to evaluate its safety and efficacy in patients with moderate COVID-19.